Peer-reviewed results in Molecular Therapy Oncology show that targeted, mutation-agnostic CRISPR gene editing of NRF2 in head and neck cancer models resensitizes treatment resistant tumors to ...

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

The company got into the game by partnering with smaller drugmakers in this field, most notably CRISPR Therapeutics. The two ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Study finds CRISPR restores the ability for cancer treatments to attack melanoma cancer cells with precision-guided gene edit that ignores healthy cells Wilmington, DE, OCTOBER 15, 2024 -- In a ...

Dr. Mark Pennesi looks on as staff at school's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial in Portland. Kristyna Wentz-Graff/OHSU ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...